TY - JOUR
T1 - A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint
AU - Mondragón, Laura
AU - Galluzzi, Lorenzo
AU - Mouhamad, Shahul
AU - Orzáez, Mar
AU - Vicencio, José Miguel
AU - Vitale, Ilio
AU - Moure, Alejandra
AU - Messeguer, Angel
AU - Perez-Paya, Enrique
AU - Kroemer, Guido
N1 - Funding Information:
Acknowledgments LM and AM are recipients of predoctoral grants from FPI—MICINN and CSIC, respectively. GK is supported by Cancéropôle Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche, and the European Commission (Apo-Sys, ChemoRes. Death-Train, RIGHT). MO acknowledges support from GVPRE/2008/275. AM and EPP are supported by grants BIO2007-60066 and CTQ 2005-00995, respectively, from the Spanish Ministry of Science and Innovation (MICINN).
PY - 2009/2/1
Y1 - 2009/2/1
N2 - QM31 represents a new class of cytoprotective agents that inhibit the formation of the apoptosome, the caspase activation complex composed by Apaf-1, cytochrome c, dATP and caspase-9. Here, we analyzed the cellular effects of QM31, as compared to the prototypic caspase inhibitor Z-VAD-fmk. QM31 was as efficient as Z-VAD-fmk in suppressing caspase-3 activation, and conferred a similar cytoprotective effect. In contrast to Z-VAD-fmk, QM31 inhibited the release of cytochrome c from mitochondria, an unforeseen property that may contribute to its pronounced cytoprotective activity. Moreover, QM31 suppressed the Apaf-1-dependent intra-S-phase DNA damage checkpoint. These results suggest that QM31 can interfere with the two known functions of Apaf-1, namely apoptosome assembly/activation and intra-S-phase cell cycle arrest. Moreover, QM31 can inhibit mitochondrial outer membrane permeabilization, an effect that is independent from its action on Apaf-1.
AB - QM31 represents a new class of cytoprotective agents that inhibit the formation of the apoptosome, the caspase activation complex composed by Apaf-1, cytochrome c, dATP and caspase-9. Here, we analyzed the cellular effects of QM31, as compared to the prototypic caspase inhibitor Z-VAD-fmk. QM31 was as efficient as Z-VAD-fmk in suppressing caspase-3 activation, and conferred a similar cytoprotective effect. In contrast to Z-VAD-fmk, QM31 inhibited the release of cytochrome c from mitochondria, an unforeseen property that may contribute to its pronounced cytoprotective activity. Moreover, QM31 suppressed the Apaf-1-dependent intra-S-phase DNA damage checkpoint. These results suggest that QM31 can interfere with the two known functions of Apaf-1, namely apoptosome assembly/activation and intra-S-phase cell cycle arrest. Moreover, QM31 can inhibit mitochondrial outer membrane permeabilization, an effect that is independent from its action on Apaf-1.
KW - Apoptosis
KW - Caspases
KW - Cell cycle
KW - Cisplatin
KW - DNA damage
KW - Mitochondria
KW - Non-small cell lung cancer (NSCLC)
UR - http://www.scopus.com/inward/record.url?scp=58849096735&partnerID=8YFLogxK
U2 - 10.1007/s10495-008-0310-x
DO - 10.1007/s10495-008-0310-x
M3 - Article
C2 - 19152031
AN - SCOPUS:58849096735
SN - 1360-8185
VL - 14
SP - 182
EP - 190
JO - Apoptosis
JF - Apoptosis
IS - 2
ER -